CEACAM5
GR370/Rabbit/Monoclonal
Gene Bio Solution CEACAM5 Antibody. Gene Bio Solution’s recombinant rabbit antibody recognizes CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5, also known as CD66e). CEACAM5 is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Gene Bio Solution’s antibody to CEACAM5 shows positivity in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbladder, urachus, salivary gland, ovary, and endocervix.
Gene Bio Solution’s recombinant antibody to CEACAM5 does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEACAM5 is not found in benign glands, stroma, or malignant prostatic cells. Gene Bio Solution’s antibody to CEACAM5 is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEACAM5+) from pleural mesotheliomas (rarely or weakly CEACAM5+). Studies have shown that CEACAM5 could be used as a therapeutic target for adenocarcinomas of lung, colon, and stomach origin.
CEACAM5 represents the founding member of the carcinoembryonic antigen (CEA) family of proteins as part of the immunoglobulin (Ig) superfamily. The extracellular CEACAM domains are critical for (i) homophilic and heterophilic intercellular adhesion molecules or (ii) act as human pathogen receptors. CEACAM5 has been found to be implicated in immune related disease and cancer including colon carcinoma.
Besides colon carcinoma, CEACAM5 protein expression has been reported for various solid tumors including but not restricted to lung adenocarcinoma, stomach adenocarcinoma, esophagus adenocarcinoma, pancreas carcinoma, gallbladder adenocarcinoma, and ovarian adenocarcinoma. However, CEACAM5 is not observed in benign stromal tissue, glands, and/or malignant prostatic cells.
The CEACAM5 Gene Bio Solution-Antibody clone ZR370 recognizes the CEACAM5 antigen distinctly. Undesired binding to nonspecific cross-reacting antigen (NCA), to human polymorphonuclear leucocytes and/or binding to a variety of normal tissues could be excluded. Thus, CEACAM5 Gene Bio Solution-Antibody clone ZR370 readily assesses CEACAM5 protein expression in human colon carcinoma and pancreas carcinoma.
Gene Bio Solution is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists.
